A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-27 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Both hard-wired (cable) and through-water electronic voice communications systems may be used with surface-supplied diving. Wired systems are more popular as there is a physical connection to the diver for gas supply in any case, and adding a cable does not change the handling characteristics of the system. Wired communications systems are more reliable and simpler to maintain than through-water systems.
Also in 1894, the civil parishes within the Wilmslow district were united into a single parish of Wilmslow, and Styal was made a separate parish. On 1 April 1936, the urban district of Wilmslow was enlarged to take in Handforth and Styal. Wilmslow Urban District Council was granted a coat of arms on 21 June 1951. Wilmslow Urban District was abolished in 1974 under the Local Government Act 1972. As part of those reforms, the area had been considered for possible inclusion within Greater Manchester, but it was ultimately decided to place it in the borough of Macclesfield. No successor parish was created for the former urban district and so it became unparished, being directly administered by Macclesfield Borough Council. In 2009, Cheshire East Council was created, taking over the functions of the borough council and Cheshire County Council, which were both abolished. In 2011, the area of the former Wilmslow Urban District was split into three new parishes called Wilmslow, Handforth, and Styal.
== Video games == Half-Life (series), a video game series developed by Valve Half-Life (video game), the first game in the series Half-Life: Blue Shift, expansion to Half-Life Half-Life: Opposing Force, expansion to Half-Life Half-Life: Decay, multiplayer expansion to Half-Life Half-Life 2, the second game in the series Half-Life 2: Lost Coast, expansion to Half-Life 2 that happens somewhere in-between chapters of Half-Life 2 Half-Life 2: Episode One, a shorter game following the events of Half-Life 2 Half-Life 2: Episode Two, a shorter game following the events of Episode One Half-Life: Alyx, a prequel to the events in Half-Life 2
Vitellogenin (VTG or less popularly known as VG) (from Latin vitellus, yolk, and genero, I produce) is a precursor of the egg yolk proteins. It is synthesized and secreted by the liver of vertebrates, fat body of insects and the hepatopancreas of crustaceans. It is transported through the blood to be taken up by pinocytosis by the growing oocytes where it becomes incorporated into yolk granules. Normally, it is only found in the blood or hemolymph of females, and can therefore be used as a biomarker in vertebrates of exposure to environmental estrogens which stimulate elevated levels in males as well as females. "Vg" is a synonymous term for the vitellogenin gene and the expressed protein. The protein product is classified as a glyco-lipo-phospho-protein, having portions of sugar, fat and phosphate added post-translationally to the apo-protein in the tissue of origin. It belongs to a family of several lipid transport proteins. Vitellogenin is an egg yolk precursor found in the females of nearly all oviparous species including fish, amphibians, reptiles, birds, most invertebrates, and monotremes. Vitellogenin is the precursor of the lipoproteins and phosphoproteins that make up most of the protein content of yolk. In the presence of estrogenic endocrine disruptive chemicals (EDCs), male fish can express the gene in a dose-dependent manner. This gene expression in male fish can be used as a molecular marker of exposure to estrogenic EDCs.
=== Other lawsuits === On April 9, 2019, Nations Restaurant News reported that Burger King filed a lawsuit on Fritz Management LLC to remove Burger King trademarks from 37 units in South Texas after unsanitary conditions were found at a restaurant in Harlingen, Texas. In May 2019, the lawsuit was settled with the franchisee, Fritz Management (a subsidiary of Sun Holdings Inc), keeping the trademarks on all 37 units.
Sources: en.wikipedia.org
== Epidemiology == Leiomyosarcomas are rare. Sarcomas combined account for less than 1% of cancer diagnoses, and leiomyosarcoma accounts for around 10% of sarcoma diagnoses. Around 63% of uterine sarcomas, 20% of abdominal sarcomas, and 15% of sarcomas of the arms and legs are leiomyosarcomas. Non-uterine leiomyosarcoma is around 40% more common in women than in men. The disease generally affects older adults with the average person diagnosed around age 60. Uterine leiomyosarcoma most commonly impacts women in perimenopause, with an average age of diagnosis at 57.
Countercurrent exchange is used extensively in biological systems for a wide variety of purposes. For example, fish use it in their gills to transfer oxygen from the surrounding water into their blood, and birds use a countercurrent heat exchanger between blood vessels in their legs to keep heat concentrated within their bodies. In vertebrates, this type of organ is referred to as a rete mirabile (originally the name of the organ in the fish gills). Mammalian kidneys use countercurrent exchange to remove water from urine so the body can retain water used to move the nitrogenous waste products (see countercurrent multiplier).
Van Buren (1829), member of New York State Assembly Henry Ledyard (1830), mayor of Detroit; president of Newport Hospital Henry Nicoll (1830), U.S. congressman from New York Henry C. Murphy (1830), U.S. congressman from New York; former U.S. ambassador to the Netherlands John L. O'Sullivan (1831), US minister to Portugal; journalist who coined the term " Manifest Destiny"; publisher of The United States Magazine and Democratic Review James William Beekman (1834), member of the New York State Senate; vice-president of the New York Hospital Isaac C. Delaplaine (1834), U.S. congressman from New York John Richardson Thurman (1835), U.S. congressman from New York John Jay (1836), grandson of Chief Justice John Jay; United States minister to Austro-Hungary; president of the American Historical Association John Vanderbilt (1837), judge, member of the New York State Senate William Ward Duffield (1841), officer, member of the Michigan Senate, superintendent of the U.S. National Geodetic Survey Abram Stevens Hewitt (1842), former mayor of New York City and planner of the first line of the New York City Subway system; Chairman of the Democratic National Committee 1876–1877, son-in-law of philanthropist Peter Cooper Edward Cooper (1842), former mayor of New York City and son of industrialist Peter Cooper Nicholas B. La Bau (1844), member of the New York State Assembly and the New York State Senate John Winthrop Chanler (1847), U.S. congressman from New York Horace Carpentier (1848), first mayor of Oakland, California and president of the Overland Telegraph Company A.
== Benefits of microchimeric cells == The severity of preexisting autoimmune disorders is reduced during pregnancy and it is most apparent when fetal microchimeric cells levels are highest - during the last trimester. These cells can also replace injured maternal cells and recover tissue function (type I diabetes mouse model showed replacement of defective maternal islet cells by fetal-derived pancreatic cells). Fetal microchimeric cells can differentiate into cell types that infiltrate and replace injured cells in models of Parkinson's disease or myocardial infarction. They also help in wound healing by neoangiogenesis. Seeding of fetal microchimeric cells into maternal tissues has been proposed to promote care of offspring after birth (seeding of maternal breast tissue may promote lactation, and seeding of brain may enhance maternal attention).
Sources: en.wikipedia.org
=== In the field === The study of birds in the field was helped enormously by improvements in optics. Photography made it possible to document birds in the field with great accuracy. High-power spotting scopes today allow observers to detect minute morphological differences that were earlier possible only by examination of the specimen "in the hand".
=== Naming === The term "type 1 diabetes" has replaced several former terms, including childhood-onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus. Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes mellitus. Beyond these two types, there is no agreed-upon standard nomenclature. Diabetes mellitus is also occasionally known as "sugar diabetes" to differentiate it from diabetes insipidus. Diabetes insipidus is an unrelated disease with symptoms that can mimic diabetes mellitus.
=== Cardiovascular system === Women are less impacted by heart disease due to vasculo-protective action of estrogen which helps in preventing atherosclerosis. It also helps in maintaining the delicate balance between fighting infections and protecting arteries from damage thus lowering the risk of cardiovascular disease. During pregnancy, high levels of estrogens increase coagulation and the risk of venous thromboembolism. Estrogens have been shown to upregulate the peptide hormone adropin, increase platelet adhesiveness, and increase the circulating level of coagulation factors 2, 7, 9, and 10, as well as plasminogens. They also decrease antithrombin III, which suppresses parts of the coagulation system.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.